These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26767432)

  • 1. Enlarging Multiple Neoplastic Skin Growths.
    Feinstein EG; Zhou M; Setabutr P
    JAMA Ophthalmol; 2016 Mar; 134(3):337-8. PubMed ID: 26767432
    [No Abstract]   [Full Text] [Related]  

  • 2. Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
    Wolfe CM; Green WH; Cognetta AB; Hatfield HK
    Dermatol Surg; 2012 Nov; 38(11):1863-6. PubMed ID: 22805146
    [No Abstract]   [Full Text] [Related]  

  • 3. Oral hedgehog-pathway inhibitors for basal-cell carcinoma.
    Lear JT
    N Engl J Med; 2012 Jun; 366(23):2225-6. PubMed ID: 22670909
    [No Abstract]   [Full Text] [Related]  

  • 4. Vismodegib in advanced basal-cell carcinoma.
    Henkin RI
    N Engl J Med; 2012 Sep; 367(10):970; author reply 970-1. PubMed ID: 22931271
    [No Abstract]   [Full Text] [Related]  

  • 5. Developing expert consensus for the use of hedgehog inhibitors in basal cell nevus syndrome.
    Lukowiak TM; Cahn B; Samie F; Leffell DJ; Oro A; Kibbi N; Kheterpal M; Babakoohi S; Khushalani NI; Stephenson A; Ma MS; Shi VJ; Ahmed A; Koza E; Haq M; Yi MD; Nadir U; Yoo S; Brieva JC; Lucas J; Haber R; Alam M
    Arch Dermatol Res; 2024 Jul; 316(7):453. PubMed ID: 38967654
    [No Abstract]   [Full Text] [Related]  

  • 6. 9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient.
    Kieny A; Kremer V; Scheidecker S; Lipsker D
    Acta Derm Venereol; 2018 Feb; 98(2):287-288. PubMed ID: 29057423
    [No Abstract]   [Full Text] [Related]  

  • 7. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
    Tang JY; Mackay-Wiggan JM; Aszterbaum M; Yauch RL; Lindgren J; Chang K; Coppola C; Chanana AM; Marji J; Bickers DR; Epstein EH
    N Engl J Med; 2012 Jun; 366(23):2180-8. PubMed ID: 22670904
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Calcium Channel Blockade on Vismodegib-Induced Muscle Cramps.
    Ally MS; Tang JY; Lindgren J; Acosta-Raphael M; Rezaee M; Chanana AM; Epstein EH
    JAMA Dermatol; 2015 Oct; 151(10):1132-4. PubMed ID: 26200175
    [No Abstract]   [Full Text] [Related]  

  • 9. Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome.
    Chang AL; Atwood SX; Tartar DM; Oro AE
    JAMA Dermatol; 2013 May; 149(5):639-41. PubMed ID: 23677114
    [No Abstract]   [Full Text] [Related]  

  • 10. Targeting the hedgehog pathway to treat basal cell carcinoma.
    Geeraert P; Williams JS; Brownell I
    J Drugs Dermatol; 2013 May; 12(5):519-23. PubMed ID: 23652945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome.
    Ally MS; Wysong A; Tang JY; Aasi S
    Dermatol Surg; 2013 Sep; 39(9):1413-4. PubMed ID: 23682843
    [No Abstract]   [Full Text] [Related]  

  • 12. Vismodegib for periocular and orbital basal cell carcinoma.
    Gill HS; Moscato EE; Chang AL; Soon S; Silkiss RZ
    JAMA Ophthalmol; 2013 Dec; 131(12):1591-4. PubMed ID: 24136169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mesenteric cysts in naevoid basal cell carcinoma syndrome: a mimic of metastatic disease.
    Rajan N; Brown S; Ward S; Hainsworth P; Hodgkinson P; Pieniazek P; Husain A; Plummer R
    Br J Dermatol; 2016 Mar; 174(3):684-5. PubMed ID: 26473628
    [No Abstract]   [Full Text] [Related]  

  • 14. Intermittent Vismodegib Therapy in Basal Cell Nevus Syndrome.
    Yang X; Dinehart SM
    JAMA Dermatol; 2016 Feb; 152(2):223-4. PubMed ID: 26509945
    [No Abstract]   [Full Text] [Related]  

  • 15. Histologic changes in basal cell carcinoma after treatment with vismodegib.
    Aldabagh B; Yu J; Perkocha LA; Arron S
    Dermatol Surg; 2013 Nov; 39(11):1703-5. PubMed ID: 23879864
    [No Abstract]   [Full Text] [Related]  

  • 16. Emerging treatments and signaling pathway inhibitors.
    Tang JY; Marghoob AA
    Semin Cutan Med Surg; 2011 Dec; 30(4 Suppl):S14-8. PubMed ID: 22177102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vismodegib (Erivedge) for basal cell carcinoma.
    Med Lett Drugs Ther; 2012 Jul; 54(1394):53-4. PubMed ID: 22777303
    [No Abstract]   [Full Text] [Related]  

  • 18. Indications and limitations of vismodegib for basal cell carcinoma.
    Yin VT; Sniegowski M; Esmaeli B
    JAMA Ophthalmol; 2014 Jul; 132(7):905-6. PubMed ID: 25010179
    [No Abstract]   [Full Text] [Related]  

  • 19. Indications and limitations of vismodegib for basal cell carcinoma--reply.
    Gill HS; Moscato EE; Silkiss RZ
    JAMA Ophthalmol; 2014 Jul; 132(7):906. PubMed ID: 25010181
    [No Abstract]   [Full Text] [Related]  

  • 20. [A new drug for basal cell carcinoma].
    Witte F
    Schweiz Monatsschr Zahnmed; 2013; 123(12):1104-6. PubMed ID: 24730087
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.